Scottish Brain Sciences (SBS), a clinical research organisation focused on early detection and treatment of Alzheimer’s disease and other neurodegenerative conditions, has opened a new clinical research centre at ONE BioHub in Aberdeen. The facility expands access to clinical trials across Scotland and strengthens the company’s capacity for precision studies in early diagnosis and intervention.

The Aberdeen centre is SBS’s third research facility, complementing its headquarters in Edinburgh and its St Andrews research hub. By joining ONE BioHub, SBS gains access to infrastructure and integrated support designed to help life sciences companies scale operations and advance innovation. The site enables people living with Alzheimer’s disease, as well as those concerned with memory issues, to participate in studies aimed at improving understanding and treatment of neurodegenerative disorders.

ONE BioHub is home to a growing network of research-focused companies, including NovaBiotics and Genomes.io. Establishing a presence in this environment allows SBS to connect brain health research with clinical and commercial pathways, further positioning Scotland as a hub for neurological innovation and contributing to the country’s broader life sciences strategy.

The Aberdeen site was officially opened on 14 November by SBS research participant Lynne Carroll, alongside Richard Lochhead MSP, Minister for Business and Employment, who highlighted the investment’s potential benefits for Scotland’s innovation economy and public health landscape.

Professor Craig Ritchie, CEO and founder of Scottish Brain Sciences, said: “The people of the north-east deserve early access to breakthroughs in brain health and dementia research. This new site will help ensure that people here can take part in trials, receive advanced assessments, and contribute to discoveries that could change the future of Alzheimer’s disease. Inviting one of our research participants to officially open this centre reflects our belief that progress begins and ends with the people who volunteer to take part. They are the beating heart of discovery.”

Lynne Carroll added: “It took several years to receive my Alzheimer’s diagnosis, and that is the reality for so many people. By being part of research that aims to detect and treat Alzheimer’s earlier, I hope I can help make the path a little clearer for others in the future. I reached out to Scottish Brain Sciences some time ago as I was eager to contribute. When they shared plans to open a research site in Aberdeen, I was thrilled, as it means I will be able to take part in trials that may require regular visits. It is a privilege to be involved in today’s opening, and I would encourage anyone locally affected by Alzheimer’s to connect with the team.”

Dr Deborah O’Neil OBE FRSE, chair of ONE Life Sciences and BioAberdeen Ltd, said: “We are delighted that Scottish Brain Science is expanding at ONE BioHub. Their focus on advancing understanding and treatment of neurological conditions adds important strengths to our growing life sciences cluster. The north east has a vibrant community of life science innovators and it is wonderful to see our first tenant growing and scaling within ONE BioHub.”